ASCO/NCODA Patient-Centered Standards for Medically Integrated Dispensing

NCODA - Going Beyond the First Fill

Oncology Institute Attendees

NCODA Medically Integrated Pharmacy Process

NCODA PATIENT PROCESS

Growth & Culture Within NCODA

NCODA CoPay Accumulator Programs

NCODA Special Webinars

The Role of R2 (REVLIMID® + RITUXIMAB®) in Previously Treated Follicular Lymphoma

NCODA Quarterly Clinical Corner

NUBEQA® (darolutamide) for Non-Metastatic Castrate Resistant Prostate Cancer &

Tukysa for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

Clinical Management of 1L Advanced RCC Patients on CABOMETYX + OPDIVO

Treatment Options For The Management Of Patients With 1L ARCC

NCODA COVID 19 Vaccine Webinar

Inrebic (fedratinib) capsules: A Treatment Option in Myelofibrosis

Reblozyl (luspatercept-aamt)

NCODA Special Webinar: December 8,2020

Nubequa (darolutamide) for Prostate Cancer

Sarclisa (Isatuximab)

Neratinib in HER2 – Positive Breast Cancer for Extended Adjuvant treatment

Neratinib Clinical Update

Neratinib Diarrhea Management PQI Overview

Neratinib Treatment Support Kit

Inrebic by Ali McBride

Ninlaro by Dr. Ralph Boccia

Onureg by Michelle Little & Emily Ackerman

Imbruvica by Chara Reid

MLEO by Dr. Imad Tbarra

Clinical Considerations for Nurses when Administering DARZALEX FASPRO by Maisha Amusa

Full NCODA Quarterly Clinical Corner - Nov 2020

New Treatment Option For Follicular Non Hodgkin’s Lymphoma by Dr. Jeffrey Schriber

Brukinsa for Mantle Cell Lymphoma by Kayla Randle

Sarclisa for Relapsed/Refractory Multiple Myeloma by Meg Butler

Padcev in Bladder Cancer by Melody Chang

Inrebic by Dr. Amit Patel

Ovarian Cancer by Natasha Olson

Sarclisa by Ali McBride

Opdivo and Yervoy by Kirollos Hanna

Tukysa by Dr. Virginia Kaklamani

OVARIAN CANCER: Identifying PARP Inhibitor Eligibility in Your Clinic

SARCLISA (isatuximab-irfc) for Relapsed/Refractory Multiple Myeloma

CABOMETYX®: Clinical Management of Advanced RCC and HCC

Padcev for Bladder Cancer - Special Webinar on 8/25/20

Ovarian Cancer EMR Resource - Aria Special Webinar on 8/25/20

Protecting Patients With NERLYNX®, the only HER2-directed small molecule approved by the FDA in both eBC and mBC

CABOMETYX®- Clinical Management of Advanced RCC and HCC

ALUNBRIG MLEO RECORDING - 7/2/20

NCODA Clinical Education Series - 7/1/20

TUKYSA™ (tucatinib) Network Training

XERMELO WEBCAST - Lisa Raff, PharmD, BCPS, BCOP

CABOMETYX®: Clinical Management of Advanced RCC & HCC

NCODA Spring E-Forum 2020

NCODA Fall Summit 2019

NCODA Fall Summit Highlight

Getting Involved - Become a Member

Physicians Involvement

Dr Stephen Grubbs ASCO-NCODA Collaboration

NCODA Spring Forum 2019

2019 Spring Forum Highlight

ASCO/NCODA Quality Standards

Earl L. "Buddy" Carter, BSPharm House of Representatives (R-Georgia)

Accreditation vs Credentialing

Tracking Medication Mail Order

Waste Reduction and Cost Avoidance

Positive Quality Intervention

TSK SPRING FORUM INTERVIEW

NCODA Fall Summit 2018

Going Beyond the First Fill

NCODA Quality Standards

2018 Fall Summit Highlight

The Rise of Oral Oncolytics

Dr. Patel on the Importance of Biosimilars

Dr. Patel on Cost-Effective Strategies for Oncologists

Dr. Patel on Skepticism Associated With Biosimilars

The Impact of Precision Medicine in Oncology

The Sustainability of Rising Drug Prices in Oncology

NCODA Spring Forum 2018

Strategies for Improving Adherence to Oral Oncolytics

The Role of the Pharmacist in Value-Based Care

Rep. Doug Collins: Providing Healthcare vs Health Insurance

Medically Integrated Dispensary in Value-Based Care

PQIs Improve Patient Interactions and Outcomes

Transitioning Patients from Infusion to Oral Chemotherapy

Addressing Adherence with Patient Education

Pharmacists Play A Key Role in Oncology Care

NCODA Fall Summit 2017

Health Care Reform: Voices Must Be Heard

Financial Assistance for Cancer Patients

Perseverence Is Key in Cancer Treatment

Pharmacist's Role in Improving Quality of Life for Patients

Patient Education on Oral Chemotherapy Medications

Filling the Gaps in Patient Coverage for Oral Chemotherapies